𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer

✍ Scribed by Matthew K. Wong; Alvis I. Lo; Bing Lam; W. K. Lam; Mary S. Ip; James C. Ho

Publisher
Springer
Year
2009
Tongue
English
Weight
197 KB
Volume
65
Category
Article
ISSN
0344-5704

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Second-line treatments after first-line
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer
✍ Jenn-Yu Wu; Jin-Yuan Shih; Chih-Hsin Yang; Kuan-Yu Chen; Chao-Chi Ho; Chong-Jen πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 236 KB

## Abstract Gefitinib is effective as first‐line therapy for advanced nonsmall cell lung cancer (NSCLC). However, after failure of gefitinib, it is unknown whether any second‐line regimens could lead to better outcomes. To study the influence of different second‐line antitumor regimens on the outco

Prognostic model to predict outcomes in
Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment
✍ Min Jae Park; Jeeyun Lee; Jung Yong Hong; Moon Ki Choi; Joon Ho Yi; Su Jin Lee; πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 437 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: A prognostic model based on clinical parameters for nonsmall cell lung cancer (NSCLC) patients treated with gefitinib (250 mg/day) as a salvage therapy was devised. ## METHODS: Clinical data regarding a total of 316 metastatic or recurrent NSCLC patients who were treat